Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

Opinion

This category features expert opinion on the latest developments in the field of cancer

Dr_Luke_Fletcher
January 30, 2023
Hematologic Malignancies/Opinion

Imetelstat in Low-Risk MDS for Transfusion Independence: the Phase 3 IMerge Study

By Luke Fletcher, MD Willamette Valley Cancer Institute & Research Center   Imetelstat, a telomerase inhibitor, has shown interesting promise for ESA refractory or unlikely to respond low-risk Myelodysplastic syndrome (MDS). In

Breast Cancer/News/Opinion

DESTINY-Breast04 Trial

By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School   “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors that do not overexpress HER2 can still derive

January 26, 2023

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Hematologic Malignancies/Opinion

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Hematologic Malignancies/Opinion

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of

Breast Cancer/Opinion

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective

More
by Tiani Grosso
March 27, 2023
Dr_Luke_Fletcher
Hematologic Malignancies/Opinion

Zuma 7 trial shows statistically significant overall survival benefit for yescarta

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates

More
by Tiani Grosso
March 23, 2023
Radhika_Kulkarni
Melanoma & Skin Cancer/Opinion

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This

More
by Tiani Grosso
March 20, 2023
Lung Cancer/Opinion

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is

More
by Tiani Grosso
March 20, 2023
Lung Cancer/Opinion

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that

More
by Tiani Grosso
March 9, 2023
GU Malignancies/Opinion

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a

More
by Tiani Grosso
March 7, 2023
Hematologic Malignancies/Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a

More
by Tiani Grosso
February 27, 2023
Hematologic Malignancies/Opinion

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,

More
by Tiani Grosso
February 17, 2023
Hematologic Malignancies/Opinion

FDA Approves Pemigatinib in Patients with Relapsed/Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Finally a Treatment Option for a Challenging Disease

By Dr. Abhishek A. Mangaonkar Mayo Clinic   The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who

More
by Tiani Grosso
February 7, 2023
Dr_Luke_Fletcher
Hematologic Malignancies/Opinion

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with

More
by Tiani Grosso
January 31, 2023
1 2 Next

your advertisement here

you may also like...

  • Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial
  • FDA_Approved
    FDA Approves Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
  • Dr. Rubina Suwal of the Binaytara Foundation Cancer Center Receives ASCO International Innovation Grant
  • Dr_Luke_Fletcher
    Zuma 7 trial shows statistically significant overall survival benefit for yescarta
  • Biomarker Testing in Advanced Non-Small Cell Lung Cancer

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty highlight FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies Lung cancer Nepal Nepal cancer care oncology oncology CME Opinion SCHD upcoming conferences video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article